How much will zotuximab cost in 2025? How will price changes affect patient choice?

Zolbetuximab (trade name VYLOY) is a targeted drug used to treat certain types of gastric cancer and gastroesophageal junction cancer. The drug has been launched in China in 2025, but due to its short time on the market, the price has not yet been clarified, and it has not been included in medical insurance. If patients need to purchase, they can consult their local hospital or pharmacy for the latest price information. Since it is not covered by medical insurance, domestic patients have to bear higher drug costs, which may affect its accessibility and scope of use.

In overseas markets, the original drug of zotuximab is available in multiple versions, such as the European version and the Japanese version. The common specification is100mg, and each box may be sold for more than 7,000 yuan. As drug pricing in different regions is affected by factors such as production costs, tax policies and market demand, prices may fluctuate. In addition, exchange rate changes may further affect patients' drug purchase costs, causing prices to differ in different countries.

Currently, there are no generic drugs of zotuximab on the market, so patients have fewer drug purchasing channels to choose from and mainly rely on domestic original drugs or overseas drug purchasing channels. For some patients with limited financial resources, high drug prices may become a major burden during treatment, which may prompt them to seek more cost-effective alternatives, such as participating in clinical trials or applying for charitable assistance programs.

In the future, if zotuximab is included in medical insurance, its price may drop, thereby reducing patients' financial burden and improving drug accessibility. In addition, as market demand grows and pharmaceutical companies expand their production scale, drug prices may also be adjusted. Once generic drugs are on the market, patients will have more choices and drug prices may fall further, benefiting more patients.

Reference materials:https://www.astellas.com/en/news/29401